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Human cytomegalovirus (CMV) remains one of the
most important pathogens following solid-organ
transplantation. Mounting evidence indicates that
mammalian target of rapamycin (mTOR) inhibitors
may decrease the incidence of CMV infection in solid-
organ recipients. Here we aimed at elucidating the
molecular mechanisms of this effect by employing
a human CMV (HCMV) infection model in human
macrophages, since myeloid cells are the principal in
vivo targets of HCMV. We demonstrate a highly di-
vergent host cell permissiveness for HCMV with opti-
mal infection susceptibility in M2 but not M1 polarized
macrophages. Employing an ultrahigh purified HCMV
stock we observed rapamycin-independent viral entry
and induction of IFN-b transcripts, but no proinflam-
matory cytokines or mitogen-activated protein kinases
and mTOR activation early after infection. However,
in the late infection phase, sustained mTOR activa-
tion was observed in HCMV-infected cells and was
required for efficient viral protein synthesis including
the viral late phase proteins pUL-44 and pp65. Accord-
ingly, rapamycin strongly suppressed CMV replication
3 and 5 days postinfection in macrophages. In conclu-
sion, these data indicate that mTOR is essential for
virus replication during late phases of the viral cycle in
myeloid cells and might explain the potent anti-CMV
effects of mTOR inhibitors after organ transplantation.
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Introduction
In transplantation medicine, human cytomegalovirus
(HCMV) infection is associated with increased acute and
chronic allograft rejection, opportunistic infections and re-
duced graft and patient survival (1–4). Without antiviral pro-
phylaxis the majority of renal transplant patients would de-
velop CMV infections (5–7). The high seroprevalence of
CMV makes reactivation from latency more frequent than
de novo infections (8,9).
CMVdisplays a broad target cell tropism including epithelial
cells, endothelial cells, fibroblasts and different hematopoi-
etic cells (10,11). The tropism of CMV for myelomonocytic
cells is essential for the viral immune escape mechanisms
mediated by effects on various immunological effector
functions (12–16). Further, monocytes and macrophages
are tightly involved in the reactivation of CMV from latency,
which is dependent on the state of macrophage differen-
tiation (17). While monocytes are targets for latent CMV
infection, macrophages sustain viral replication in vitro and
in vivo (18–20). Macrophages are found in a variety of dif-
ferent phenotypes in the body playing a fundamental role
in immune-mediated renal disease, host defense, but also
renal allograft responses (21). Macrophage differentiation
depends on the cellular microenvironment resulting in dis-
tinct phenotypes ranging from proinflammatory M1-type
to tissue-remodeling M2-type macrophages (22). Recent
evidence suggests that HCMV reprograms monocytes to
acquire a proinflammatory M1 phenotype to facilitate vi-
ral spread (23). Currently, however, it is unclear, whether
macrophage subsets differ in their susceptibility to CMV
infection.
mTOR exists in two complexes, mTORC1 and mTORC2,
whereas inhibition of mTORC1 is part of current
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immunosuppressive protocols. Recent evidence
from various studies consistently demonstrated re-
duced CMV infections with mTORC1 inhibitor-based
immunosuppressive therapy both when employed de
novo as part of an immunosuppressive regimen and after
conversion to an mTOR inhibitor (24–26). However, the
detailed molecular mechanisms responsible for these
beneficial antiviral effects have not been elucidated so far.
CMV has a low replicative cycle and must deal with the in-
hibitory effects of the stress response associated with viral
entry. Hence CMV activates the PI3K-Akt-mTOR pathway
including the mTORC1 downstream effectors S6 riboso-
mal protein and the translation factor 4E-BP-1 (27,28). Fur-
ther, CMVwas reported to encodemTORC1-activating pro-
teins like pUL38 blocking TSC2, which negatively regulates
mTOR, thereby providing survival signals for infected cells
(29,30). Additionally, CMV induces a substrate-specific al-
teration of mTORC1 activity, since CMV-infected fibrob-
lasts display a resistance against the inhibitory effects of
rapamycin enabling hyperphosphorylation of 4E-BP1, while
S6 phosphorylation remains rapamycin sensitive (28). Re-
cently, Raptor, an essential component of the mTORC1
complex, was demonstrated to be essential for viral pro-
tein synthesis in fibroblasts (27), while in other cell types
HCMV even blocked the PI3K-Akt-mTOR pathway possi-
bly to avoid detrimental effects for the virus (31). In addi-
tion, rapamycin was reported to be ineffective in the inhibi-
tion of CMV replication and protein synthesis in fibroblasts
(11,28,32).
Here we report that HCMV is able to productively infect
human M2 polarized macrophages in an mTOR-dependent
manner, while M1 polarized macrophages do not rep-
resent suitable host cells to support HCMV replication
in vitro. Activity of mTOR was induced at late but not
early time points by HCMV infection and was an essential
prerequisite for successful CMV replication in human M2
macrophages. Given the general importance of the mono-
cyte/macrophage system for HCMV persistence, suppres-
sion of viral replication by mTOR inhibition at late phases of
the viral cycle might explain the beneficial effects of mTOR
inhibitors on CMV incidence after allogeneic transplanta-
tion.
Materials and Methods
Cell isolation and culture
Human monocytes were purified from peripheral blood mononuclear cells
as described (33). RPMI 1640 (Gibco BRL, Carlsbad, CA, USA) supple-
mented with 2 mM L-glutamine, 100 lg/mL streptomycin, 100 U/mL peni-
cillin and 10% fetal calf serum (FCS; Hyclone, South Logan, UT, USA) was
used as culture medium. Primary human foreskin fibroblasts (HFF) were
used for experiments between passages 5 and 12 and were cultured in
Dulbecco’s Modified Eagle Medium (Gibco BRL, Grand Island, NY, USA)
supplemented with 1.75 g glucose/500 mL, 2 mM L-glutamine, 100 lg/mL
streptomycin, 100 U/mL penicillin and 10% FCS. Macrophages were cul-
tured in serum-freemedium (SFM;Macrophage SFM,Gibco) supplemented
with 2% FCS, 100 lg/mL streptomycin and 100 U/mL penicillin. Rapamycin
(Sigma Deisenhofen, Germany) treatment was performed for 90 min at a
concentration of 100 nM with DMSO as a solvent control in all untreated
samples.
Macrophage differentiation and polarization
CD14+monocytes were suspended in RPMI 1640 medium supplemented
with 10% FCS at a density of 7.5 × 105 cells/mL. Recombinant hu-
man M-CSF (Peprotech, Rocky Hill, NJ, USA) was added to a final con-
centration of 50 ng/mL, and 4 mL of the cell suspension (3 × 106
cells) were seeded per six wells. Cells were allowed to differentiate for
6 days. After the differentiation period, cells were gently resuspended
and washed once with prewarmed macrophage SFM. Cell density was
adjusted to 1.7 × 105 cells/mL before seeding to different well sizes
at a density of 300 lL/cm2. After allowing cells to settle and adhere
for 1 h at 37◦C, polarization was induced by setting final concentra-
tions of 1 lg/mL LPS (Escherichia coli 0111:B4, Sigma) in combination
with 20 ng/mL IFN-c (R&D #285-IF) (M1 polarization) or 20 ng/mL IL-
4 (Peprotech #200-04) (M2 polarization). After 24 h, polarization medium
was removed and adherent cultures were washed once with prewarmed
macrophage SFM followed by addition of fresh prewarmed macrophage
SFMmedium. After another 24 h of resting, cells were infectedwith virus as
described.
Macrophage infection
For short time incubations (up to 48 h), virus stock dilutions were added
to rapamycin or solvent-treated cultures to reach 10 plaque forming units
(PFUs)/cell followed by subsequent incubation for the indicated periods. For
long-term infections, virus was added to the cultures at 10 PFUs/cell and
removed after an adsorption phase of 2 h at 37◦C bywashing twicewith pre-
warmed macrophage SFM. Finally, macrophage SFM supplemented with
2% FCS followed by addition of 100 nM rapamycin or solvent was added.
Virus propagation and virus stock preparation
HCMV strain TB-40/E was kindly provided by U. Koszinowski and propa-
gated for a maximum of 10 cycles in HFF cells by infecting 80% conflu-
ent HFF cultures with an M.O.I. (Multiplicity of Infection) of 0.1 PFU/mL.
Virus stocks were obtained by employing a protocol adapted from Chen
and Pagano (34) to reach a sufficient high purity for macrophage exper-
iments. After the cytopathic effect in the propagation culture reached
100% between day 10 and 12, supernatant was precleared from cel-
lular debris by 1 h centrifugation at 4◦C and 4500 g. Supernatant was
carefully applied onto a precooled 30% iodixanol cushion (q = 1.178
g/mL) in ultracentrifuge tubes (SW-28, Beckman Coulter, Indianapolis, IN,
USA). The iso-osmotic density cushion was obtained by dilution of Visi-
paqueTM (Amersham Pharmacia Biotech, Uppsala, Sweden) in PBS. Fol-
lowing centrifugation for 1 h at 4◦C (23 000 rpm, 100 000 g), culture
medium was removed by aspiration followed by an additional overlay of the
iodixanol cushion with PBS in order to prevent potential contaminations
of the virus stock with culture medium components. After completely re-
moving PBS and the iodixanol cushion by aspiration, the virus pellet was
resuspended in 2 mL of macrophage SFM. Single use aliquots were snap
frozen in liquid nitrogen and stored at –80◦C until use. Virus stock inactiva-
tion was performed either by 100 kDa molecular weight cut-off filtration or
by exposure to UV light for 5 min using a transilluminator.
An isolate of HCMV was obtained from a renal transplant patient with
HCMV disease and freshly used for the infection of macrophage cul-
tures without passaging in fibroblasts. Viral genomes were quantified by
reverse-transcriptase polymerase chain reaction (RT-PCR) yielding 5 × 106
copies/mL plasma.
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Virus titer assays
PFUs per milliliters were determined by infecting HFF monolayers with
serial dilutions of virus stocks and culture supernatants in 96-well triplicates
as described (35).
ELISA
Cytokines were measured from cell-free supernatants by Luminex assays
from R&D Systems (Minneapolis, MN, USA). IFN-b was determined with
an ELISA kit (VeriKine Human IFN Beta Elisa Kit, PBL).
Quantitative RT-PCR
Macrophages were cultured in 6-well plates and pretreated as indicated
followed by infection with TB-40/E or inactivated virus. Total RNA was ex-
tracted in TRIzol 6 h postinfection and cDNA was generated by Super-
script II (Invitrogen, Carlsbad, CA, USA) as suggested by the manufacturer.
mRNA levels were determined by TaqMan Gene Expression Assays (Ap-
plied Biosystems, Carlsbad, CA, USA) on an ABI Prism 7000 in a multiplex
PCR. IFN-b mRNA levels were normalized to 18S rRNA.
The number of HCMV genomes per milliliter of culture supernatant was
determined by a quantitative real-time PCR assay, as previously published
(36).
Western blot analysis
Extract preparation and immunoblotting was done as described (33). An-
tibodies used were against IE-1 (NEA-9221), pUL-44 (CMV ICP36 Mono-
clonal Antibody, Virusys, Taneytown, MD, USA), GAPDH, TF-II/D (TBP (N-
12), sc-104, Santa Cruz, Santa Cruz, CA, USA), Histone-H3 (Cell Signal,
Danvers, MA, USA), S6- (54D2, #2317, Cell Signal), p-S6(240/244) (#2215,
Cell Signal), p-ERK1/2 ((Tyr204) (sc-7383, Santa Cruz), p-p38 (Thr180/Tyr182)
(#9211, Cell Signal), IjBa (#9242 Cell Signal), according to recommenda-
tions on datasheets.
Immunocytochemistry
Macrophages were cultured in 8-well PermanoxTM chamber slides (Lab-Tek
Chamber Slide System 177402). Staining was performed as described 36.
Antibodies against p-S6(240/244) (Cell Signal), IE-1 (NEA-9221) and pp65
(Clonab-CMV) were used at 1:50 dilutions. Secondary antibodies (GAR
Alexa Fluor 488 F(ab′)2 fragment of goat antirabbit IgG (H+L) 2 mg/mL Invit-
rogen, GAM Alexa Fluor 594 F(ab′)2 fragment of goat antirabbit IgG (H+L)
2 mg/mL Invitrogen) were used at a 1:200 dilution. Images were taken on
an Olympus Provis AX-70 fluorescence microscope equipped with a digital
camera (Olympus XC-50).
Infection efficacy of CMV in macrophages
Macrophage cultures were stained for IE-1 antigen and Hoechst-33342.
Infection efficacy was determined by counting the number of IE-1-positive
cells in a field of vision containing at least 100 cells. The number of IE-1-
positive cells per field of vision was related to the number of total cells
(Hoechst-33342 positive) giving the percentage of infected cells per field
of vision. Three fields of vision were counted followed by calculation of the
arithmetic mean for an individual experiment.
Statistics
Cytokine levels, RNA levels and virus titers were compared using Student’s
t-test. In all experiments, differences were considered statistically signifi-
cant at p < 0.05.
Results
Macrophage subtype differentiation defines
susceptibility to HCMV infection
Monocyte-derived macrophage subsets play a fundamen-
tal role in the allograft response, however, it is un-
known whether different subsets influence CMV dissem-
ination and persistence. Hence, we generated M1 (LPS
plus IFN-c ) and M2 (IL-4) macrophages and evaluated
their permissiveness for CMV TB-40/E infection by as-
sessing viral immediate early protein expression (IE-1).
While M2 macrophages could be efficiently infected, a
significantly decreased IE-1 expression was seen in M1
macrophages (Figures 1A–C). Interestingly, a strong dif-
ference in HCMV susceptibility was already existent only
4 h after macrophage polarization (Figure 1D). We used
UV-inactivated virus as well as molecular weight cut-off fil-
trated virus stock as negative controls for our experiments.
Both inactivation procedures completely abrogated CMV
infection (Figure 1D and Figure S1).
To further examine M2 macrophage-specific CMV infec-
tion by a virus stock that was not propagated from hu-
man fibroblasts, we coincubated fresh plasma from a
CMV-infected viremic renal transplant patient with M2
macrophages at 10 genomes per cell. Remarkably, after
3 weeks of culture, CMV-positive cells were identified
by typical morphological changes and nuclear inclusions
demonstrating that patient-derived CMV successfully in-
fects and replicates in M2 macrophages (Figure 1E).
HCMV does not induce cytokine responsiveness and
virus entry-associated signaling in M2 macrophages
As CMV was reported to activate inflammatory cytokine
and chemokine expression in several innate immune
cell types, we assessed IL-6, IL-10, IL-12 and TNF-a
production in monocytes and macrophages. As both,
monocytes and macrophages express functional Toll-like
receptors (TLR), LPS stimulation was used as a positive
control for functional cytokine responses in our cultures.
In contrast to LPS stimulation, after HCMV infection for
24 h neither monocytes nor M2 macrophages produced
significant amounts of any of the cytokines tested (Figures
2A and B). In line with the cytokine phenotype we could
not identify an induction of mitogen-activated protein ki-
nases or NF-jB, important mediators of cytokine signaling
(Figure 2C). Similarly, we found no activation of the mTOR
pathway as assessed by phosphorylation of the ribosomal
protein S6 during the early phase of HCMV infection in M2
macrophages (Figure 2C).
HCMV infection of M2 macrophages culminates in an
mTORC1-independent type-I interferon response
Next, we investigated whether the type-I interferon re-
sponse, which is the prototypical antiviral immune re-
sponse, is activated in M2 macrophages; HCMV potently
induced IFN-b in M2 macrophages while UV-inactivated
virus failed to induce an IFN-b response (Figures 3A and
B) suggesting that only live HCMV induces a type-I in-
terferon response in M2 macrophages. Interestingly, ra-
pamycin neither affected IFN-b mRNA transcription nor
IFN-b protein expression (Figures 3A and B). There was
no induction of IFN-a1 detected following HCMV infec-
tion of M2 macrophages (data not shown). These results
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Figure 1: Infection susceptibility of M1 versus M2
macrophages by CMV. (A) M-CSF differentiated macrophages
were generated as described in Materials and Methods. Rep-
resentative image showing differences in TB-40/E infection
efficacy between M1 and M2 macrophages with 10 PFU/mL
24 h postinfection. (B) The percentage of IE-1-positive cells of
CMV-infected M1 and M2 macrophages was counted and the
mean ±SEM is shown for four independent experiments. (C)
CMV-infected M1 and M2 macrophages were analyzed 24 h
postinfection for IE-1 expression by immunoblot. A representative
experiment out of three is depicted. (D) M-CSF differentiated
collectively indicate that M2 macrophages selectively
produce an mTORC1-independent type-I interferon but not
a typical proinflammatory cytokine response upon HCMV
infection.
Rapamycin efficiently blocks CMV replication in M2
macrophages
Analyzing the effects of mTORC1 inhibition at later time
points of the viral replication cycle, we found that ra-
pamycin significantly suppressed CMV replication in M2
macrophages on days 3 and 5 postinfection, while CMV
proliferation in fibroblasts was only moderately decreased
by mTORC1 inhibition on day 5 but not on day 3
(Figure 4A). RT-PCR analysis of infected culture super-
natant on day 5 post-CMV infection revealed that the in-
hibition of CMV proliferation reached a maximum already
at 10 nM rapamycin (Figure 4A, right-hand side), which is
in the range of physiologic levels reached during patient
treatments with the immunosuppressant. HCMV-infected
M2 macrophages remarkably increased their cell motil-
ity indicated by extensive cell polarization, which was de-
creased by rapamycin (Figure 4B).While CMV-positive cells
could be identified via CMV-specific nuclear inclusions
(Figure 4B, arrows), rapamycin strongly reduced number
and size of these nuclear inclusions (Figure 4B). Further-
more, the expression of the late phase viral protein pUL-44
was inhibited by rapamycin in a concentration-dependent
manner, as indicated by western blot analysis of infected
cultures on day 5 postinfection with CMV (Figure 4C, right-
hand side). As shown in Figure 4C (left-hand side), ra-
pamycin reduced the number of CMV-infected and adher-
ing cells indicated by weaker signals for Histone-H3 and
GAPDH at days 5 and 7 postinfection.
Early phases of CMV infection in macrophages are
independent of mTORC1 activity
The suppressive effect of rapamycin on CMV replication
suggested that mTORC1 might be critical for CMV infec-
tion. Therefore, we systematically assessed viral gene ex-
pression and mTORC1 activity during the course of M2
macrophage infection. mTORC1 activation was not asso-
ciated with IE1 gene expression in infected cells 24 h
and 48 h postinfection (Figure 5A). Infected cells, which
could be easily identified by nuclear expression of the
viral antigen IE-1, did not show increased levels of
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
macrophages were either co-incubated with LPS (1 lg/mL), IL-4
(20 ng/mL), IL-13 (20 ng/mL) or LPS+IFNc (1 lg/mL + 20 ng/mL).
After 4 h, 10 PFU/cell of TB-40/E was added per well and allowed
to attach to cells for 2 h followed by a change of culture medium;
24 h postinfection, cells were fixed and three independent exper-
iments were analyzed for the percentage of IE-1-positive cells as
described in the Methods section. (E) Photomicrographs showing
M2 macrophages 3 weeks after 1 h of co-incubation with plasma
drawn from a CMV viremia patient and control plasma (Mock) di-
luted 1:10 in serum-free culture medium or control macrophages
(white bars: 50 lm).
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Figure 2: Effect of CMV infection on cytokine production and
early signaling events in monocytes and M2 macrophages.
CD14+ monocytes or M2 macrophages were infected with TB-
40/E or stimulated with LPS for 24 h. TNF-a, IL-6, IL-12 and IL10
were determined in the supernatants by luminex analysis. The
mean cytokine concentration ±SEM in cultures of monocytes (A,
n= 4) and macrophages (B, n= 5) is shown. (C) M2 macrophages
were incubated with CMV, UV-inactivated virus stock (UV) and
Figure 3: CMV-mediated type I-interferon induction in M2
macrophages. (A) mRNA was prepared from M2 macrophages
following 6 h of co-incubation with HCMV, HCMV plus 100 nM ra-
pamycin (CMV+R), UV-inactivated virus (UV) and medium alone.
mRNA levels were analyzed by quantitative RT-PCR and are shown
as the mean ± SEM relative to HCMV-infected sample (n = 3). (B)
M2macrophages were either infected with CMV or mock infected
and cultured in the absence and presence of 100 nM rapamycin.
Supernatants were analyzed for IFN-b secretion at the indicated
time points. Results are expressed as the mean ± SEM of four
independent donors (n = 4).
ribosomal protein S6 phosphorylation compared to unin-
fected cells in the cultures. Moreover, rapamycin did not
affect the infection efficiency of macrophages as indicated
by similar percentages of IE-1-positive cells at 24 h and 48 h
postinfection in the presence and absence of rapamycin
(Figure 5B). Immunoblot analysis further established that
the expression of IE-1 is independent of mTORC1 and that
a complete loss of IE-1 protein signals occurs between
day 1 and day 4 after macrophage infection (Figure 5C).
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
LPS for the indicated time periods and whole-cell lysates were
analyzed by immunoblotting. The experiment is representative of
three independent donors.
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Figure 4: The effect of rapamycin on CMV replication and
CMV-induced cytopathology in M2 macrophages. (A) M2
macrophages and fibroblast (HFF) cells were treated with UV-
inactivated CMV (gray bars) or infected with TB-40/E in the ab-
sence (black bars) or presence (white bars) of 100 nM rapamycin.
Supernatant aliquots were taken on day 3 and day 5 postinfection
and virus copy numbers were determined by RT-PCR (n = 4) (left).
Indicated concentrations of rapamycin were added tomacrophage
cultures immediately following infection with CMV. Supernatants
were analyzed for virus copy numbers following 5 days of culture
in the presence of rapamycin (right). (B) Photomicrographs of rep-
resentative cultures ofM2macrophages infected with 10 PFU/cell
TB-40/E after 5 days in the presence or absence of rapamycin are
depicted in low (left) and high (right) magnification (white bars:
50 lm). (C) M2 macrophages were incubated with CMV, UV-
inactivated virus stock (UV) and LPS and whole-cell lysates were
analyzed by immunoblotting at the indicated time points (left). Ex-
pression of pUL-44, GAPDH and Histone-H3 in infected (CMV)
and mock-infected (UV) cells were analyzed following treatment
with indicated concentrations of rapamycin (right) for 5 days. The
experiments are representative of three independent donors.
Similarly, in multinucleated giant cells (MNGCs) that de-
velop in macrophage cultures, there was no correlation
between IE-1 expression and cellular mTORC1 activity as-
sessed by S6 phosphorylation (Figure 5D).
Figure 5: mTORC1 activity in early phases of macrophage in-
fection by TB-40/E. (A) After treatment with rapamycin (CMV+R)
or solvent control (CMV), M2 macrophages were infected with
TB-40/E. Cultures were fixed at the indicated time points postin-
fection and double stained for p-S6 (green) and IE-1protein (red).
Hoechst-33342 channel is shown below to control cell numbers
in the fields of vision (white bar: 50 lm). (B) The percentages
of IE-1-positive cells at day 1 and day 2 postinfection are given
comparing solvent control (black) and 100 nM rapamycin (white)-
treated M2macrophage cultures by determination of the infection
rate in three independent experiments. (C) Analysis of IE-1 expres-
sion by western blot on day 0, day 1 and day 4 postinfection of
M2 macrophages with UV-inactivated TB-40/E (UV), living TB-40/E
(CMV) and living TB-40/E in the presence of 100 nM rapamycin
(CMV+R). (D) Representative immunocytochemistry staining for
p-S6 (green) and IE-1 (red) on day 1 postinfection showingMNGCs
developing in M2 macrophage cultures during polarization and in-
fection (white bar: 50 lm).
Late phase CMV infection is linked to enhanced
mTOR activation
Our experiments suggested that pUL-44 protein synthe-
sis and HCMV replication are affected by rapamycin in
M2 macrophages, while early phases of the HCMV in-
fection/replication cycle were found to be independent
of mTORC1 in M2 macrophages. mTORC1 is essential
for various cellular functions including cell growth, protein
synthesis and cell motility (37–39). Especially late phases
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Figure 6: Ribosomal protein S6
activity in TB-40/E infected M2
macrophages at late phases of viral
replication. (A) Photomicrographs of
M2 macrophage cultures at day 2 and
day 5 postinfection with TB-40/E are
shown. Cells were fixed at indicated
time points and stained for p-S6
(green) and pp65 (red). Morphology
and nuclear structure are presented
by differential interference contrast
(DIC) images and Hoechst-33342 stain.
White arrows indicate cytoplasmic and
nuclear inclusions caused by productive
CMV infection (white bars: 50 lm). (B)
Cultures were treated as in (A) followed
by immunofluorescence staining of
p-S6 (green) in combination with IE-1
(red) and Hoechst-33342 (white bars:
50 lm).
of the viral replication require a high rate of protein syn-
thesis, which is essential for efficient production of virus
particles. Immunofluorescence triple stains for the viral
tegument protein pp65 that increases with the rate of pro-
duction of viral particles, phosphorylated ribosomal pro-
tein S6, and DNA were performed to investigate CMV-
mediated mTORC1 activation at the single cell level. As
depicted in Figure 6A, pp65 was expressed at low levels in
the nuclei of infected cells along with increased S6 phos-
phorylation on day 2 postinfection. After three further days
of culture pp65-positive cells were present in the culture
while the localization of the viral tegument protein changed
from an exclusively nuclear to a strong whole cell signal.
The signal for nuclear pp65 gradually increased over time
while morphological cytopathic effects including large nu-
clear and cytoplasmic inclusions appearedmore frequently
(Figure 6A, white arrows). The terminal phase of CMV in-
fection is characterized by excessive cell rounding and a
strong but diffuse pp65 signal signifying the presence of
viral particles in the cytoplasmic compartment. Further, a
nuclear transition from a condensed to a low-density state
was observed between early and late pp65-positive cells
and was also prominent in MNGCs in macrophage cul-
tures (Figure S3). Only the pp65-positive macrophages and
MNGCs at day 5 postinfection displayed S6 phosphoryla-
tion (Figure 6A). Furthermore, late phase-infected cells also
displayed high levels of nuclear IE-1 (Figure 6B).
HCMV late phase-induced activation of ribosomal
protein S6 in macrophages is mediated through
mTORC1
CMV was reported to induce rapamycin-insensitive phos-
phorylation of S6 in fibroblast cultures (28). Our exper-
iments demonstrated that rapamycin efficiently blocks
CMV replication in M2 macrophages and that mTOR is
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markedly hyperactivated in these cells in late phases dur-
ing CMV infection. To investigate the rapamycin sensitivity
of CMV induced mTOR activation, we employed western
blot analysis of cultures, whereas different concentrations
of rapamycin were added 48 h following CMV infection.
CMV potently enhanced S6 phosphorylation in infected
cultures in the absence of rapamycin. The effect was highly
sensitive to inhibition by rapamycin as S6 phosphorylation
was completely abrogated at 1 nM rapamycin. Simulta-
neously with the inhibition of S6 phosphorylation, the ex-
pression of the late phase viral protein pUL-44 was effi-
ciently repressed in the presence of low concentrations
of rapamycin (Figure 7A). Furthermore, we assessed the
sensitivity of CMV-induced S6 phosphorylation for inhibi-
tion by rapamycin by immunofluorescence analysis of a
CMV-infected macrophage culture treated with 100 nM
rapamycin for 90 min on day 5 postinfection (Figure 7B,
left panel). The solvent- and the rapamycin-treated cul-
tures contained cells showing nuclear as well as whole
cell localization of the viral tegument protein pp65. The
selective increase of protein S6 phosphorylation in pp65-
positive cells points to an infection-mediated increase in
mTORC1 activity during late phases of viral replication. As
depicted in the right panel of Figure 7(B), rapamycin com-
pletely suppressed CMV infection-induced S6 phosphory-
lation demonstrating that mTORC1 is essential for the en-
hanced S6 phosphorylation that is exclusively observed in
pp65-positive, CMV-infected M2 macrophages.
Discussion
Our results demonstrate that suppressing mTORC1 ac-
tivity potently blocks HCMV replication in polarized
macrophages. While recent data found a critical role for
mTORC1 for HCMV lytic replication in fibroblasts, our re-
sults imply an essential requirement of mTORC1 activity
adjusting the substantially increased rate of ribosomal ac-
tivity in immunocompetent cells with late viral gene ex-
pression during CMV infection. Since macrophages play
a pivotal role in the propagation of CMV infection, our
data indicate that the clinically observed anti-CMV bene-
fits in transplant recipients treated with mTOR inhibitors
may also occur by a direct blockade of HCMV replication
at the level of myeloid immunocompetent cells.
CMV infection is one of the most important complications
following solid organ transplantation and occurs in 44–
85% of untreated transplant recipients, most commonly
during the first 3 months posttransplantation when im-
munosuppression is most intense. Two mTOR inhibitors
that have been investigated for use in the de novo renal
transplantation setting are the macrocyclic lactone antibi-
otic sirolimus and its derivative everolimus. The ability of
both sirolimus and everolimus to prevent acute rejection
in renal transplant recipients has been demonstrated in
several clinical investigations (40–45). Interestingly, it was
found that mTOR inhibitors have strong anti-CMV effects in
Figure 7: HCMV-mediated protein S6 activation is mediated
through mTORC1. M2 macrophages were infected with TB-40/E
(CMV) or UV-inactivated virus (UV): (A) Forty-eight hours follow-
ing infection, either solvent (0) or indicated concentrations of ra-
pamycin were added to the cultures. On day 5 postinfection, cells
were recovered and analyzed for expression levels of the viral late
phase protein pUL-44, phosphorylated protein S6 and Histone-H3.
(B) On day 5 postinfection, solvent (left) or rapamycin (right) was
added to CMV-infected cultures. After 90 min of incubation at
37◦C, cells were fixed and immunofluorescence double stains for
p-S6 (green) and pp65 (red) were employed. Images are shown
together with DIC channel and nuclear staining using Hoechst-
33342 (white bars: 50 lm).
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kidney-transplanted patients (25). Thus far, however, only
a limited number of preclinical studies have been con-
ducted to analyze the anti-CMV mechanisms of action for
the mTOR inhibitors.
We and others could recently identify mTOR as a criti-
cal regulator of the innate immune system (33,46). Since
CMV can effectively subvert the host immune response by
several complex mechanisms, we initially postulated that
CMV might engage mTOR at the myeloid cell level to alter
the innate immune response for host evasion. However,
we found that CMV did not activate intracellular cascades
such as MAPK or NF-kB and no significant proinflamma-
tory cytokine responses. The HCMV–macrophage inter-
action, however, was still productive since a significant
IRF-3- and IRF-7-driven production of type-I IFN-b was
detected albeit in an mTORC1-independent manner and
CMV readily induced intense morphological alterations
comparable to CMV-infected fibroblast cultures along with
increased cell motility and widespread cell polarization
(Figure 3 and data not shown). While a significant num-
ber of studies on the immunomodulatory properties of hu-
man CMV (HCMV) employed virus stocks obtained from
lytic fibroblast infection without sufficient virus purifica-
tion, we applied special effort on the preparation of a
virus stock, which is free of immune modulating con-
taminants. Without ultracentrifugation through a density
cushion, our HCMV preparations also triggered high lev-
els of proinflammatory cytokines in polarizedmacrophages
along with strong intracellular activation patterns (data not
shown). However, we considered that the elimination of
potent confounding signals generated by proinflammatory
cytokines or intracellular danger molecules within the cul-
ture supernatant is a conditio sine qua non to diligently
dissect potential immunomodulatory properties of HCMV
from intracellular signaling events in the context of mTOR
activation. Further, it is known that the tropism of a CMV
laboratory strain can change during in vitro propagation
due to changes in the viral genome (47); hence we also
aimed to employ CMV preparations directly from CMV
diseased renal transplant patients which confirmed the
principle finding that HCMV can successfully infect M2
macrophages.
Our experiments revealed that pUL-44 protein synthe-
sis and CMV replication are strongly affected by ra-
pamycin in M2 macrophages, while early phases of the
CMV infection/replication cycle in M2 macrophages in-
cluding IE1 protein expression were found to be in-
dependent of mTORC1. These data are in agreement
with recent findings by Moorman and Shenk, who
demonstrated that both rapamycin and the direct ser-
ine/threonine inhibitor of mTOR torin1 could not affect
HCMV entry and IE1 accumulation in fibroblasts (32).
In line, assessment of polarized macrophages at later
time points revealed exquisite sensitivity to mTORC1
inhibition, while in accordance with previous results we
found that mTORC1 inhibition only moderately affected
viral replication in fibroblasts (28,32). As evidenced by
strongly reduced CMV-specific nuclear inclusions and also
by completely abolished pUL-44 signals at least 5 days
postinfection, mTORC1 is crucially involved in the main-
tenance of viral replication during later phases of the infec-
tious cycle. Especially late phases of the viral replication re-
quire a high rate of protein synthesis essential for efficient
production of virus particles. The remarkable increase in
cell size andmotility of CMV-infectedM2macrophages fur-
ther supports the involvement ofmTORC1 in late phases of
CMV infection (Figure 4B). These data indicate a substan-
tially increased rate of ribosomal activity in CMV-infected
M2 macrophages being tightly associated with late viral
gene expression.
Several recent reports demonstrated that CMV induces
mTOR activity presumably to increase translation of viral
proteins (32,48). Furthermore, it has been shown by Moor-
man et al. that HCMV encodes a protein, pUL38 that binds
to and inhibits TSC1/2, the principal mTORC1 negative reg-
ulator, allowing for constant mTORC1 activation (29). How-
ever, HCMV induces a distinct set of molecular changes in
the canonical mTOR signaling pathway, hence rapamycin
still efficiently blocks phosphorylation of the mTORC1 ef-
fector S6, but it can no longer prevent phosphorylation of
the other effector 4EBP. This rapamycin-resistance of at
least CMV-infected fibroblasts still lacks a molecular ex-
planation, but was hypothesized to be present to ensure
efficient and robust viral replication (32). Our data are in
line with the findings of a critical role of mTORC1 for virus
replication: while several data on herpesvirus replication
show that the PI3-K-mTOR signaling axis becomes acti-
vated early after infection and may also be critical for infec-
tious efficiency, our data rather suggest an importance of
mTORC1 activity during later time points after infection. In-
terestingly, the number of IE-1-positive cells was found to
decrease significantly between 24 and 48 h postinfection
with CMV. While a small percentage of IE-1-positive cells
continued in the viral life cycle as indicated by expression
of the viral late phase protein pp65, the majority of IE-1-
positive cells shut down IE-1 expression again, entering a
state of latency.
Differentiation and functional specification is a central fea-
ture of macrophages critically affecting their immunolog-
ical features including the allograft response. Unlike M1
macrophages that show enhanced production of proin-
flammatory cytokines (TNF-a, IL-6 and IL-12) and increased
generation of reactive oxygen species such as NO that
may also mediate allograft rejection, M2 macrophages
are generally characterized by low levels of proinflam-
matory cytokines and high expression of antiinflamma-
tory cytokines (IL-12low and IL-10high) (49,50). Hence, M2
macrophages have immunoregulatory and immunosup-
pressive functions. Previous studies demonstrated that
reactivation of CMV from latently infected CD14 mono-
cytes is dependent on cellular differentiation induced
by allo-cytokines that are able to induce macrophage
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differentiation and virus production (17). We found that
monocyte-derived M2-type macrophages are highly sus-
ceptible to CMV infection in contrast to M1 macrophages
(Figure 1) indicating that allo-cytokine differentiation may
promote an M2-like macrophage phenotype. Together,
these findings suggest a potential involvement of M2
macrophages in CMV reactivation following solid-organ
transplantation. The local cytokine milieu in the graft may
lead to M2-type macrophage differentiation of recruited
macrophages which in turn drives CMV reactivation from
latency and enhances the permissiveness of de novo CMV
infection.
In conclusion, we have demonstrated that HCMV effi-
ciently infected human polarized M2 macrophages, while
M1macrophageswere resistant toward infection. Counter-
intuitively, we found that HCMV did not exert early signal-
ing events along with absent inflammatory cytokine induc-
tion, whereas IFN-b production was triggered at significant
amounts upon viral entry. The complete independence of
mTORC1 activity was superseded by a strong dependence
of viral replication on mTORC1 activity at later time points
of the viral life cycle with a profound suppression of viral
replication by rapamycin. As monocytes and macrophages
cells are pivotal for host persistence and continuing viral
replication of CMV as part of their immunoevasive strate-
gies, our data argue for a direct antiviral effect of currently
employedmTOR inhibitors rather than an interference with
potent immunomodulatory effects exerted by CMV.Molec-
ular analysis of the various antiviral mechanisms engaged
by mTORC1 inhibitors within prospective trials in organ
transplant patients might finally resolve the final role of
mTORC1 as an essential component for CMV infection
and disease.
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